AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04341857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Monoclonal Antibody(Sintilimab)
Description: Sintilimab combined with FLOT regimen,Docetaxel#50mg/m2d1,iv infusion for 1 hour#,Oxaliplatin#80mg/m2d1#iv infusion for 2 hours#,Calcium,leucovate#200mg/m2d1#iv infusion# ,Fluorouracil#2600mg/m2,intravenous drip for 24h# Every 14 days is one cycle# Sintilimab#200mg, d1#iv infusion Every 21 days is one cycle.
Study NCT01985074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case-management intervention
Description: The participants in the intervention group receives a nurse-managed case-management intervention that is regularly delivered by telephone or, when necessary, in person.
Study NCT02016313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy
Study NCT02016313 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: physiotherapy
Study NCT02933021 — intervention group
Intervention type: OTHER
Intervention: Blood sample taken
Study NCT02933021 — intervention group
Intervention type: OTHER
Intervention: Answering a lifestyle questionnaire
Study NCT02933021 — intervention group
Intervention type: OTHER
Intervention: Follow-up phone call from researcher (two years after first visit)
Description: To enquire about status of participants monoclonal gammopathy of unknown significance, and whether there has been progression to multiple myeloma.
Study NCT03621358 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control gummy with free flavour (without encapsulating)
Description: 12 g/day (3 gummies)
Study NCT03621358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental gummy with 50% free/50% encapsulated flavour
Description: 12 g/day (3 gummies)
Study NCT00432068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide pamoate
Study NCT00700193 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Influenza Virus Vaccine
Description: 2 dose vaccine regimen: 2 X 0.25mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose
Study NCT00700193 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Influenza Virus Vaccine
Description: 2 dose vaccine regimen: 2 X 0.50mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose
Study NCT04865289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.
Study NCT04865289 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV infusion given on Day 1 of each cycle.
Study NCT04865289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each cycle.
Study NCT04865289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.
Study NCT01494324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT guided percutaneous ablation
Description: Depending on tumor size and location, we will direct a core biopsy needle in the ablated tumor using post-ablation dynamic Liver CT guidance, preferably including liver triphasic examination. The obtained tissue will be detached, collected and submitted to our molecular cytology laboratory. All specimens will be submitted fresh to our molecular cytology laboratory for immediate analysis in order to classify them as viable tumor (V) or apoptotic cells/coagulation necrosis (CN). CT will be performed within 24 hours of the ablation to demonstrate the ablation defect, representing the area of coagulation necrosis. This CT will be used for targeting the ablated tumor for biopsy. All patients will undergo CT again, approximately within 4-8 weeks (+/- 2 weeks) of percutaneous ablation to evaluate for CN in the target tumor or any sign of residual tissue enhancement, representing incomplete treatment.
Study NCT00577694 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: clofarabine
Description: Intravenous, 20mg/m2, Days 1, 2, 3, 4 and 5; 2 cycles
Study NCT00577694 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: gemtuzumab ozogamicin
Description: Intravenous, 3mg/m2, Day 1, one cycle
Study NCT03621358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental gummy with 100% encapsulated flavour
Description: 12 g/day (3 gummies)
Study NCT02875158 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophotocoagulation protocol
Description: * Intravenous route is installed~* Retrobulbar anaesthesia : 50% xylocaine (2%) + 50% bupivicaine~* Parameters set for laser treatment (1250mW-4seconds or 2000mW-2 seconds depending on the assigned group)~* Pars plana measurement using transillumination (if needed)~* Laser treatment applied approximately 1mm post to limbus~* Dexamethasone 0,5 mg subconjunctival injection~* Post-op regimen: Prednisolone 1% qid x 4 weeks, Atropine 1% bid x 2 weeks + Erythromycin ointment + patch x 6h
Study NCT03949868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Mindfulness
Description: Those in the high mindfulness group will also receive questions about their memory performance over the past 30 minutes in both the morning and evening for six days. In order to emphasize the variability in pain, participants will receive these text messages on a variable schedule. In addition, they will sent instructions every morning to pay attention to variability in their memory performance throughout the day and asked to report on how their memory performance is changing over time as a part of each text message prompt.
Study NCT03949868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Mindfulness
Description: Those in the low mindfulness group, who will receive receive two text messages per day (one at at 9am and one at 8pm) for six days, each prompting them to write about the activity they are currently engaged in. They will also be prompted with the 9am text to report on their memory performance over the past 30 minutes.
Study NCT03936270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Letrozole will be supplied as a 2.5 mg film-coated tablet. It must be taken at the recommended dose of 2.5 mg once daily.
Study NCT03402269 — intervention group
Intervention type: OTHER
Intervention: Clavicle fracture injury- observation
Description: The study is an observational study with assessments at 1 month, 3 months, 6 months and 1 year following injury. Assessments include range of motion, strength, patient reported outcomes and radiographic healing
Study NCT02875158 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cyclophotocoagulation protocol
Description: * Intravenous route is installed~* Retrobulbar anaesthesia : 50% xylocaine (2%) + 50% bupivicaine~* Parameters set for laser treatment (1250mW-4seconds or 2000mW-2 seconds depending on the assigned group)~* Pars plana measurement using transillumination (if needed)~* Laser treatment applied approximately 1mm post to limbus~* Dexamethasone 0,5 mg subconjunctival injection~* Post-op regimen: Prednisolone 1% qid x 4 weeks, Atropine 1% bid x 2 weeks + Erythromycin ointment + patch x 6h
Study NCT02875158 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cyclophotocoagulation
Description: 1250 mW for 4 seconds.
Study NCT02875158 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified cyclophotocoagulation
Description: 2000 mW for 2 seconds.
Study NCT02122406 — intervention group
Intervention type: OTHER
Intervention: Hospital Anxiety and Depression Scale (HADS) questionnaire
Description: Patients filled in the Hospital Anxiety and Depression Scale (HADS) questionnaire
Study NCT00073242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leptin
Description: leptin administration
Study NCT00073242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary modification
Description: Subjects lose 10% of body weight via dietary restriction
Study NCT00073242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T3 repletion
Description: administer T3
Study NCT04868136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 30 minutes of exercise at 80% of maximum predicted heart rate performed on an indoor stationary bicycle. Exercise was preceded by 10 min of gradually increasing cycling intensity in one of two exercise trials
Study NCT03726281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg, IV
Study NCT00826449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Starting dose of 70 mg by mouth daily for 21 day cycle.
Study NCT00826449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg by mouth daily every 21 day cycle.
Study NCT00334100 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Treadmill exercise
Study NCT03768726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: All investigational products will be provided by Pfizer and will include oral ziprasidone capsules of 20, 40, 60, and 80 mg strength. Matching placebo capsules will also be supplied for the initial 1-14 day dose transition period. During the transition period all subjects will receive both active ziprasidone and placebo capsules. The placebo capsules are used to maintain the blind to the treatment assignment of the subjects in A1281198 . All medication will be packaged in childproof blister cards with columns for AM and for PM capsules. During the dose transition period (Weeks 1-2, Days 1-14), subjects will receive a study drug blister card for each week of transition dosing. Subjects weighing greater than 45 kg will receive 2 weeks of transition medication, while subjects weighing less than 45 kg will receive 1 week of transition medication.
Study NCT03768726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: All investigational products will be provided by Pfizer and will include oral ziprasidone capsules of 20, 40, 60, and 80 mg strength. Matching placebo capsules will also be supplied for the initial 1-14 day dose transition period. During the transition period all subjects will receive both active ziprasidone and placebo capsules. The placebo capsules are used to maintain the blind to the treatment assignment of the subjects in A1281198 . All medication will be packaged in childproof blister cards with columns for AM and for PM capsules. During the dose transition period (Weeks 1-2, Days 1-14), subjects will receive a study drug blister card for each week of transition dosing. Subjects weighing greater than 45 kg will receive 2 weeks of transition medication, while subjects weighing less than 45 kg will receive 1 week of transition medication.
Study NCT00444093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opii normata treatment
Description: After beginning of diarrhea grade 1:~5 drops tincture of opium three times a day~After beginning of diarrhea grade 2:~Intensive therapy with 15 drops tincture of opium three times a day.
Study NCT00444093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamid Treatment
Description: All patients who receive as a result of randomisation loperamide~After beginning of diarrhea grade 1:~Initial 4mg and 2mg after any unformed stool. The maximum dose amounts to16mg per day.~After beginning of diarrhea grade 2:~Intensive therapy with 2mg loperamide every 2 h. The maximum dose amounts to 16mg per day.
Study NCT00324766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levosimendan
Description: 1 h infusion, 0.2 microgs/kg/min, 24 h infusion,0.1 microgs/kg/min
Study NCT00324766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo,
Description: 24 h, infusion
Study NCT03544996 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: TD Insulin
Description: Human Insulin USP formulated in a solution capable of transdermal delivery.
Study NCT01725776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled milrinone 5 mg
Description: Inhaled milrinone 5 mg (as for the injectable solution)
Study NCT03972267 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Free gingival graft
Description: Free Gingival Graft removal from the palate donor area for socket preservation
Study NCT03972267 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free gingival graft
Description: Free Gingival Graft removal from the palate donor area for socket preservation
Study NCT03972267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enamel Matrix Derivate
Description: EMD in contact with the palate wound for 5 min. After this time, palatal area will be covered with an individualized acetate plate which will stay in position for 2 hours after the procedure
Study NCT05219461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of rhEGF 10mcg/ml or placebo
Description: 6 subjects will be assigned to rhEGF 10mcg/ml eye drop and 2 subjects will be assigned to placebo
Study NCT05219461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of rhEGF 50mcg/ml or placebo
Description: 6 subjects will be assigned to rhEGF 50mcg/ml eye drop and 2 subjects will be assigned to placebo
Study NCT05219461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of rhEGF 100mcg/ml or placebo
Description: 6 subjects will be assigned to rhEGF 100mcg/ml eye drop and 2 subjects will be assigned to placebo
Study NCT05219461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple dose of rhEGF 10mcg/ml or placebo
Description: 6 subjects will be assigned to rhEGF 10mcg/ml eye drop and 2 subjects will be assigned to placebo
Study NCT05219461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple dose of rhEGF 50mcg/ml or placebo
Description: 6 subjects will be assigned to rhEGF 50mcg/ml eye drop and 2 subjects will be assigned to placebo
Study NCT05219461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple dose of rhEGF 100mcg/ml or placebo
Description: 6 subjects will be assigned to rhEGF 100mcg/ml eye drop and 2 subjects will be assigned to placebo
Study NCT01218113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 or 3 doses according to protocol schedule
Study NCT02027883 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nominal T shock setting
Description: Nominal Parameter Set 1 Programming Values for EnTrust
Study NCT02027883 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Educated T shock setting
Description: Experimental Parameter Set 2 Programming Values
Study NCT03613844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA
Description: DHA supplementation
Study NCT02141113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guanfacine Hydrocholride
Description: 1. mg Guanfacine Hydrochloride (orally)~2. mg Guanfacine Hydrochloride (orally)~3. mg Guanfacine Hydrochloride (orally)~4. mg Guanfacine Hydrochloride (orally)~5. mg Guanfacine Hydrochloride (orally)~6. mg Guanfacine Hydrochloride (orally)
Study NCT02141113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Guanfacine Hydrocholride
Description: 1. mg Guanfacine Hydrochloride (orally)~2. mg Guanfacine Hydrochloride (orally)~3. mg Guanfacine Hydrochloride (orally)~4. mg Guanfacine Hydrochloride (orally)~5. mg Guanfacine Hydrochloride (orally)~6. mg Guanfacine Hydrochloride (orally)
Study NCT01545024 — intervention group
Intervention type: DRUG
Intervention: Sitagliptin, 50 mg once per day per os
Description: Before and one year after treatment with DPP-IV inhibitor in diabetic patients with AND.
Study NCT00833807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel (Abraxane)
Description: Day 1 of Cycles 1-6, Starting Dose of 130 mg/m2 received through arterial catheter over 30 minutes. Cycle is 21 Days.~Day 1 of Cycle 7+, Dose received through catheter in vein over 30 minutes. Cycle is 21 Days.
Study NCT03029897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: My eReport France
Description: patients are educated to the use of My eReport France application
Study NCT03734562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Substrate-based radiofrequency catheter ablation
Study NCT03734562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic drug
Description: Amiodarone or sotalol therapy
Study NCT01022151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo [group P]
Description: receive intravenous injection of 0.2 mL/kg of saline 0.9%L \[group P\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
Study NCT01022151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2 mL/kg of aminophylline 10 mg/mL [group A2]
Description: receive intravenous injection of 0.2 mL/kg of aminophylline 10 mg/mL \[group A2\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
Study NCT01022151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2 mL/kg of aminophylline 15 mg/mL [group A3]
Description: receive intravenous injection of 0.2 mL/kg of aminophylline 15 mg/mL \[group A3\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
Study NCT01022151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2 mL/kg of aminophylline 20 mg/mL [group A4]
Description: receive intravenous injection of 0.2 mL/kg of aminophylline 20 mg/mL \[group A4\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
Study NCT01022151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2 mL/kg of aminophylline 25 mg/mL [group A5]
Description: receive intravenous injection of 0.2 mL/kg of aminophylline 25 mg/mL \[group A5\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
Study NCT00673153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemtuzumab ozogamicin
Description: Given IV
Study NCT00673153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study NCT00673153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00879892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: xenon
Description: Gas, 24 hour inhalation, en tidal target concentration 40%
Study NCT00879892 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypothermia
Description: 24 hour, target core temperature 33
Study NCT01323465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex and rifampicin
Description: Single dose of 4 sprays Sativex on Day 1, Rifampicin 2 x 300 mg capsules on Days 2-10, Sativex dose of 4 sprays and rifampicin 2 x 300 mg capsules on Day 11.
Study NCT01323465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex and rifampicin
Description: Rifampicin 2 x 300 mg capsules on Days 1-9, Sativex x 4 sprays and rifampicin 2 x 300 mg capsules on Day 10, Single dose of Sativex 4 sprays on Day 18.
Study NCT01323465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex and ketoconazole
Description: Single dose of 4 sprays Sativex on Day 1, ketoconazole 2 x 200 mg tablets on Days 2-5, Sativex x 4 sprays and ketoconazole 2 x 200mg on Day 6.
Study NCT01323465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex and ketoconazole
Description: Ketoconazole 2 x 200 mg tablets on Days 1-4, Sativex x 4 sprays and ketoconazole 2 x 200 mg tablets on Day 5, Single dose of 4 sprays Sativex on Day 9.
Study NCT01323465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex and omeprazole
Description: Single dose of 4 sprays of Sativex on Day 1 Omeprazole 2 x 20 mg on Days 2-6. Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 9.
Study NCT01323465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex and omeprazole
Description: Omeprazole 2 x 20 mg on Days 1-5, Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 6, Single dose of 4 sprays Sativex on Day 9.
Study NCT03949868 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Participants in the active control group will receive 2 text messages per day for six days (one at 9am and one at 8pm) asking them to report on the activity they are currently engaged in.
Study NCT02207543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical telephone contact
Description: Evaluations will be conducted by telephone 15 days after hospital discharge, 30 days and then every month until 6 months.
Study NCT02309658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Patients received intravenous 500-1000 ml normal saline and antiemetic medication before chemotherapy. Treatment consisted of intravenous gemcitabine at a dose of 1000 mg/m2 diluted in 500 ml of normal saline administered over 30 minutes mg/m2 diluted in 500 ml of normal saline administered over 30 minutes on days 1 and 8, followed by cisplatin 35 mg/m2 administered over 2 hours on day 1 and 8.
Study NCT02309658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 35 mg/m2 administered over 2 hours on day 1 and 8.
Study NCT02309658 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chemoradiation
Description: external beam radiotherapy concomitant with weekly cisplatin 40mg/m2